There is no basic trend for IMMUNITYBIO INC. and in the short term, there are still few sellers. It is difficult to advise a trading direction under these conditions. The first support is located at
Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international shareholder and consumer rights litigation firm, reminds investors that the deadline to move for lead plaintiff in a securities class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX ) (“ImmunityBio” or the “Company”) and certain other defendants (collectively, “Defendants”) is August 29, 2023 . CLICK HERE TO RECEIVE ADDITIONAL INFORMATION ABOUT THIS CLASS ACTION The action, which was filed in the U.S....